The Egyptian Heart Journal

2013

DOI: 10.1016/j.ehj.2012.11.002

|View full text |Cite

|

Sign up to set email alerts

|

Relationship of apolipoprotein E polymorphism with lipid profiles in atherosclerotic coronary artery disease

Ibrahim Elmadbouh

¹

,

Yasser Elghobashy

²

,

³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion2

Introduction1

Citation Types

Supporting

2

Mentioning

3

Contrasting

0

Unclassified

2

Year Published

2014

2014

2024

2024

Publication Types

Select...

Article7

Relationship

Self Cite0

Independent7

Authors

Journals

Cited by 10 publications

(7 citation statements)

References 31 publications

Supporting

2

Mentioning

3

Contrasting

0

Unclassified

2

Order By: Relevance

“…Our current study showed that frequencies of the ApoE genotype and alleles were unique in this population and associated with hyperuricemia risk. Our current data are consistent with previous studies by Moriwaki [ 27 ], Elmadbouh et al [ 28 ] and others [ 29 ]. Furthermore, our current study also showed that the SUA level in the male Uygur was statistically significant between different genotypes i.e.…”

Section: Discussionsupporting

confidence: 94%

Association of apolipoprotein E (ApoE) polymorphisms with risk of primary hyperuricemia in Uygur men, Xinjiang, China

¹

,

²

,

³

et al. 2015

Lipids Health Dis

View full text Add to dashboard Cite

BackgroundApolipoprotein E (ApoE) participates in lipoprotein metabolism and immune regulation. This study assessed association between ApoE polymorphisms with hyperuricemia and uric acid metabolism in Uygur men, Xinjiang, China.MethodsA total of 474 hyperuricemia patients and 518 healthy male controls were recruited from the Health Screening Center, Uygur region of Xinjiang, China and subjected to ApoE genotyping using a multiplex amplification refractory mutation system PCR.ResultsApolipoprotein E3/3 genotype was the predominant type with a frequency of 67.7%, while E2/2 was lower than E4/4 in Uygur males. The frequencies of ApoE2, E3, and E4 alleles were 8.5%, 80.1% and 11.4%, respectively. Distribution of ApoE genotypes was significantly different in hyperuricemia patients from the healthy controls (p < 0.001). Particularly, the frequency of ApoE E3/3 was 71.7%, E2/3 9.3%, E3/4 9.3%, E4/4 3.2%, E2/4 2.3%, and E2/2 0.2% in patients vs. 68.1%, 4.6%, 2.9%, 12%, 0.6%, and 4.6% in controls, respectively. Moreover, frequency of ApoE E2 allele was greater in the healthy controls than in patients (p < 0.001) and the highest level of uric acid occurred in those with ApoE2/4 and E3/4 genotypes, whereas the lowest uric acid level occurred in those with ApoE E2/2 genotype. In addition, the subjects with the ApoE2 allele had a lower uric acid and LDL-C level than those with the ApoE3 allele and ApoE4 allele (p < 0.05). The risk of developing hyperuricemia in subjects without the ApoE2 allele was 1.7 fold higher than those subjects with the ApoE2 allele.ConclusionsThis study revealed frequencies and distributions of ApoE alleles and genotypes in Uygur males, which are different from Han Chinese. ApoE E4 was associated with a slightly higher risk of primary hyperuricemia, whereas ApoE E2 was associated with reduced risk of primary hyperuricemia and LDL-C level.

“…Our current study showed that frequencies of the ApoE genotype and alleles were unique in this population and associated with hyperuricemia risk. Our current data are consistent with previous studies by Moriwaki [ 27 ], Elmadbouh et al [ 28 ] and others [ 29 ]. Furthermore, our current study also showed that the SUA level in the male Uygur was statistically significant between different genotypes i.e.…”

Section: Discussionsupporting

confidence: 94%

Association of apolipoprotein E (ApoE) polymorphisms with risk of primary hyperuricemia in Uygur men, Xinjiang, China

¹

,

²

,

³

et al. 2015

Lipids Health Dis

View full text Add to dashboard Cite

BackgroundApolipoprotein E (ApoE) participates in lipoprotein metabolism and immune regulation. This study assessed association between ApoE polymorphisms with hyperuricemia and uric acid metabolism in Uygur men, Xinjiang, China.MethodsA total of 474 hyperuricemia patients and 518 healthy male controls were recruited from the Health Screening Center, Uygur region of Xinjiang, China and subjected to ApoE genotyping using a multiplex amplification refractory mutation system PCR.ResultsApolipoprotein E3/3 genotype was the predominant type with a frequency of 67.7%, while E2/2 was lower than E4/4 in Uygur males. The frequencies of ApoE2, E3, and E4 alleles were 8.5%, 80.1% and 11.4%, respectively. Distribution of ApoE genotypes was significantly different in hyperuricemia patients from the healthy controls (p < 0.001). Particularly, the frequency of ApoE E3/3 was 71.7%, E2/3 9.3%, E3/4 9.3%, E4/4 3.2%, E2/4 2.3%, and E2/2 0.2% in patients vs. 68.1%, 4.6%, 2.9%, 12%, 0.6%, and 4.6% in controls, respectively. Moreover, frequency of ApoE E2 allele was greater in the healthy controls than in patients (p < 0.001) and the highest level of uric acid occurred in those with ApoE2/4 and E3/4 genotypes, whereas the lowest uric acid level occurred in those with ApoE E2/2 genotype. In addition, the subjects with the ApoE2 allele had a lower uric acid and LDL-C level than those with the ApoE3 allele and ApoE4 allele (p < 0.05). The risk of developing hyperuricemia in subjects without the ApoE2 allele was 1.7 fold higher than those subjects with the ApoE2 allele.ConclusionsThis study revealed frequencies and distributions of ApoE alleles and genotypes in Uygur males, which are different from Han Chinese. ApoE E4 was associated with a slightly higher risk of primary hyperuricemia, whereas ApoE E2 was associated with reduced risk of primary hyperuricemia and LDL-C level.

“…Concerning the Apo E gene polymorphism in the present study, it was observed that the carriers of E4 allele and especially E3/E4 genotype were at higher risk of CHD with OR = 3.3 (95% CI = 1.02–10.94) for both. These findings are more or less similar to that detected by Elmadbouh et al 54 in Egypt, Attila et al 55 in Turkey, Kharrazi et al 56 in Iran who showed that the E3/E4 genotype was statistically significantly higher in CHD patients compared to the controls.…”

Section: Discussionsupporting

confidence: 91%

Endothelial nitric oxide synthase Glu 298 Asp (G894T) and Apolipoprotein E gene polymorphism as possible risk factors for coronary heart disease among Egyptians

¹

,

²

,

³

et al. 2018

The Egyptian Heart Journal

View full text Add to dashboard Cite

In Egypt, The prevalence of chronic heart disease (CHD) is 8.3%. It is the principal cause of death and is responsible for 22% of total mortality. The age-adjusted mortality rate is 174 per 100,000 of population. There are many studies on traditional risk factors and CHD in Egypt but the study of novel risk factors is deficient.ObjectivesThe aim of the present case control study was to investigate the relation between CHD susceptibility and Endothelial Nitric Oxide Synthase (eNOS) Glu 298 Asp (G894T) and Apolipoprotein E (ApoE) gene polymorphism in a cohort of Egyptian individuals.MethodsGenotyping of eNOS (Glu298Asp) and Apo E genes polymorphisms were done using polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP) method for 100 CHD cases and 100 age and sex matched healthy controls.ResultsA statistically significant association was observed between GT and TT genotypes of endothelial nitric oxide synthase gene with CHD with OR = 2.03 and 3.5; respectively. Also, carriers of E4 allele and especially E3/E4 genotype were at higher risk of CHD with OR = 3.3 for both. Significant association was also observed between the presence of combined GTE3E4 genotype and CHD with OR = 6.6.ConclusionGT and TT genotypes of endothelial nitric oxide synthase gene, E3/E4 genotype of Apo E gene polymorphism and combined GTE3E4 genotype can be considered risk factors for the development of CHD among Egyptians.

“…Механизм возникновения этих эффектов сложен и изучен не полностью. Тем не менее, под-тверждение этих эффектов в ряде исследований [10,11] делает препараты из класса статинов одними из ведущих лекарственных средств для первичной и вторичной профилактики ишемической болезни сердца (ИБС) и других атеросклеротических сосу-дистых поражений, при этом статины оттеснили на второй план традиционные гиполипидемические средства -никотиновую кислоту, фибраты.…”

unclassified

“…Механизм токсиче-ского влияния до сих пор окончательно неясен. Есть данные о существенных изменениях метаболизма ХС и активности ферментов дыхательной цепи в миоци-тах пациентов, принимающих высокие дозы аторва-статина [11]. Известно также, что ряд факторов могут повышать риск развития миопатии при приеме стати-нов -к ним относятся гипотиреоз, нарушения функ-ции печени, сахарный диабет, алкоголь и тяжелая физическая нагрузка, а также семейный анамнез мио-патии, впрочем, не только статин-индуцированной [12].…”

unclassified

Complex Assessment of Efficacy of Statins Prescribed at Most by Clinicians

¹

,

²

,

³

et al. 2018

Cardiovasc Ther Prev

View full text Add to dashboard Cite

Aim. To evaluate a complex clinical efficacy, tolerability and safety of statin drugs — simvastatin, atorvastatin, rosuvastatin in patients with hyperlipidemia (HL).Material and methods. The assessment of clinical efficacy was done in 90 patients with HL and arterial hypertension of the grades 1 and 2, age 40-75 y.o.; some of them had coronary heart disease.Results. In 90 patients with cardiac pathology and HL, selected to 3 groups by 30 persons, the clinical efficacy of the listed statins was assessed. A significant hypolipidemic effect was noted as a decline of atherogenicity of the blood, with slight more prominent effect of rosuvastatin.Conclusion. The data makes it to conclude the simvastatin, atorvastatin and rosuvastatin are equally effective hypolipidemic drugs in HL type IIA and IIB patients. The time frame, type and grade of positive changes in lipid profile are almost the same, and in rosuvastatin just slightly more prominent.

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Product

Browser Extension Assistant by scite Citation Statement Search Reference Check Visualizations Dashboards Explore Journals Explore Organizations Explore Funders Embedding Badge Embedding Citation Search Pricing

Resources

Blog Help & FAQ Accessibility Statement API Terms For Universities & Governments For Researchers For Publishers For Corporate, Pharma & Enterprise Author Marketing Become an Affiliate Get an organization trial or quote scite Data & Services

About

News & Press Careers Read our Paper Coverage

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Copyright © 2024 scite LLC. All rights reserved.

Made with 💙 for researchers

Part of the Research Solutions Family.